Pinedo-Donelli S, Ball PE

Language: Spanish
References: 25
Page: 30-37
PDF size: 422.14 Kb.

ABSTRACT

The immune system is a group of structures and processes that allow the organism to maintain homeostasis and protect it against disease. It is highly trained to prevent the development of autoimmunity. In the past few years, the concept of «immune checkpoints» has become important. They are inhibitory pathways that regulate the immune responses in peripheral tissues. The programmed cell death receptor (PD-1) pathway represents one of these checkpoints and its main function is the development of self-tolerance. Some tumor cells are capable of overexpressing this receptor and its ligands, being recognized by the immune system as cells of the organism, thus preventing its attack and destruction. The objectives of this review will be to define the pathway of the PD-1 receptor and its ligands, to highlight its role as an immune checkpoint and the importance of its aberrant expression in the tumor microenvironment, its role in the development of immunotherapy against metastatic melanoma and to provide information on the drugs developed as blockers of this pathway.

REFERENCES

1. Kim J, Eder J. Prospects for targeting PD-1 and PD-L1 in various tumor types. Oncology. 2014; 28: 15-28.

2. Francisco LM, Sage PT, Sharpe AH. PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2011; 236: 219-242.

3. Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control. 2014; 21 (3): 231-237.

4. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015; 125 (9): 3384-3391.

5. Dana Farber. The science of PD-1 and immunotherapy. Boston: The Institute; 2015.

6. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008; 14 (10): 3044-3051.

7. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12 (4): 252-264.

8. Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metastasis. 2009; 26 (10): 19-34.

9. American Cancer Society. What is cancer immunotherapy? New York: The Institute; 2015.

10. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999; 11 (2): 141-151.

11. Sakaguchi S, Wing K, Miyara M. Regulatory T cells —a brief history and perspective. Eur J Immunol. 2007; 37 (1): S116-123.

12. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson C. Regulatory T cells in cancer. Adv Cancer Res. 2010; 107: 57-117.

13. Rosell R, Karachaliou N, Morales-Espinosa D, Costa C, Molina MA, Sansano I et al. Adaptive resistance to targeted therapies in cancer. Transl Lung Cancer Res. 2013; 2 (3): 152-159.

14. My cancer genome. PD-1 Inhibition and PD-1 Inhibitors; 2015. Disponible en: www.mycancergenome.org/content/drug-class/pd-1-inhibition-and-inhibitors/

15. Torchia A. Medicina traslacional: nuevo paradigma y nuevo desafío. Rev Cient = Hosp El Cruce [Internet]. 2015; 15 (3): 28-32. Available from: http://www.hospitalelcruce.org/revis15/art4.pdf

16. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28 (19): 3167-3175.

17. FDA. Drug approval and databases. Maryland: The Institute; 2015. Available in: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm478493.htm

18. Atkins M, Kudchadkar R, Sznol M, Mcdermott D, Lotem M, Schachter J et al. Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. J Clin Oncol. 2014; 32 (5): 1-10.

19. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014; 32 (10): 1020-1030.

20. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372 (26): 2521-2532.

21. Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015; 6 (6): 3479-3492.

22. Kelly K, Patel MR, Infante JR, Nicholas Iannotti, Petros Nikolinakos JL, Wang D et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study. J Clin Oncol. 2015; 3030-3044.

23. Zielinski CC. A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors. Transl Lung Cancer Res. 2014; 3 (6): 406-407.

24. Roche laboratories. Early data on investigational cancer immunotherapy atezolizumab in combination with Zelboraf in patients with BRAFV600 mutant-positive metastatic melanoma. Baseel (Suiza). The Institute; 2015.

25. Rutkowski P, Kozak K. News of the melanoma sessions of the European Cancer Congress 2017. BMC Medicine. 2017; 15 (57): 1-3.